# Alzamend Neuro (ALZN) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ALZN
## Company Profile
- Ticker: ALZN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CNS
## Stock Data
- Close: 1.7 USD
- Market cap: 4337404.739999999 USD
- Last updated: 2026-09-03
## Business Overview
Alzamend Neuro is a neuroscience company focused on Alzheimer's disease and other neuropsychiatric disorders. Its story is built around high-risk CNS development and novel treatment approaches.
## Why The Stock Is Moving

As of Sep 3, 2026, ALZN was little changed and closed at $1.70. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Alzamend sits in specialty biotechnology.

## Business Model

The company depends on clinical validation, safety, and the ability to build a credible neuroscience franchise.

## Landscape Position

Alzamend is a highly catalyst-sensitive CNS name whose valuation is tied to early clinical progress.

## Future Catalysts

- Alzamend’s catalysts are AL001 and any CNS-development step that keeps the platform alive. The company still needs stronger clinical proof.

## Recent News
- 2026-08-20 12:00 EST — [Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC](https://biopharmsignal.com/news/ALZN/alzamend-neuro-s-phase-1-2a-lithium-neuroimaging-data-accepted-for-poster-presen-00dbbbef) — Source: Alzamend Neuro
- 2026-08-18 12:00 EST — [Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain](https://biopharmsignal.com/news/ALZN/alzamend-neuro-s-phase-1-2a-lithium-imaging-data-accepted-for-oral-presentation--17b524eb) — Source: Alzamend Neuro
- 2026-08-04 12:00 EST — [Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending](https://biopharmsignal.com/news/ALZN/alzamend-neuro-announces-initial-closing-of-securities-purchase-agreement-with-a-65090ea0) — Source: Alzamend Neuro
- 2026-04-07 12:00 EST — [Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital](https://biopharmsignal.com/news/ALZN/alzamend-neuro-reports-encouraging-pharmacodynamic-data-from-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-in-a-trial-conducted-at-massachusetts-general-hospital) — Source: Alzamend Neuro
- 2026-03-26 12:00 EST — [Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions](https://biopharmsignal.com/news/ALZN/alzamend-neuro-reports-positive-topline-data-from-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-al001-achieves-bioequivalence-and-demonstrates-superior-brain-delivery-across-all-measured-brain-regions) — Source: Alzamend Neuro